Nifurtimox Inhibits the Progression of Neuroblastoma in vivo.

Abstract

Neuroblastoma was one of the most life-threatening cancer developed in children, yet the conventional therapies currently used leave an unmet gap for clinical requirements. Temozolomide is the first line of drug in the treatment of neuroblastorma nowadays. Giving the fact that temozolomide treatment offered limited healing effect and patients responded divergently, an alternative beneficial path is urgently requested. Nifurtimox, a drug against Trypanosoma cruzi, was happened to find competent in treating a patient who carried aggressive neuroblastoma. Although in vitro studies demonstrated that nifurtimox has cytotoxic features against tumor cells, a systematic investigation in vivo is generally inadequate. Here we exhibited that nifurtimox could suppress the progression of neuroblastoma in vivo, while maintain the health condition to a great extent. Importantly, as comparing to temozolomide, nifurtimox presented a stronger effect on inhibiting tumor development, strongly suggesting that nifurtimox is a preferential alternative drug in treating neuroblastoma. Additionally, it was shown that Akt-GSK3β signaling cascade was involved in tumor arrest induced by nifurtimox.

• Authors: Eryan Kong, Jiangli Zhu, Wentao Wu, Hongguang Ren, Xuemiao Jiao, Hui Wang, Zhongjian Zhang
• Journal: Journal of Cancer (J Cancer) Vol. 10 Issue 10 Pg. 2194-2204 ( 2019) ISSN: 1837-9664 [Print] Australia
• PMID: 31258723 (Publication Type: Journal Article)